Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 28, 2017. The report details the grant of conditional share awards to Executive Directors and Persons Discharging Managerial Responsibilities (PDMRs) under the 2017 Performance Share Plan (2017 PSP) on July 27, 2017. The plan was approved by shareholders on May 4, 2017, and covers a performance period of three financial years from January 1, 2017, to December 31, 2019.
Key Financial Metrics and Performance Targets
The filing does not report actual revenue, profit, cash flow, or debt figures for the period. Instead, it establishes performance targets for executive compensation vesting:
- Performance Measures: Awards are based on three equally weighted metrics: Total Shareholder Return (TSR), Adjusted Free Cash Flow (AFCF), and R&D new product performance.
- Adjusted Free Cash Flow (AFCF) Targets (2017 Awards):
- Threshold: £11.47 billion (25% vesting)
- Mid-point: £11.82 billion (50% vesting)
- Maximum: £13.59 billion (100% vesting)
- TSR Comparator Group: GSK is compared against AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Johnson & Johnson, Merck, Novartis, Pfizer, Roche Holdings, and Sanofi.
Material Changes and Updates
The filing discloses a material update to the performance targets for the 2016 Awards. Following the Q2 2017 results, the Remuneration Committee revised the AFCF targets downward to reflect increased planned investment in R&D, specifically related to the Pharmaceuticals business and HIV. The 2015 Awards targets remain unaffected.
| Performance Level | Original 2016 Target (£bn) | Updated 2016 Target (£bn) |
|---|---|---|
| Threshold (25% vesting) | 11.65 | 11.35 |
| Mid-point (50% vesting) | 12.01 | 11.70 |
| Maximum (100% vesting) | 13.81 | 13.46 |
Outlook, Risks, and Unusual Items
Management Commentary: The Committee stated that updating the 2016 AFCF targets is in the best long-term interests of the Company to account for increased R&D investment.
Risks and Contingencies:
- Vesting Risk: If performance thresholds are not met, awards will lapse. For TSR, 0% vests if GSK ranks 6th or lower in the comparator group.
- Confidentiality: Specific R&D new product targets are not disclosed due to commercial sensitivity and will only be revealed at the end of the performance period.
- Dividend Accrual: Dividends accrue on conditional awards but only vest if the underlying awards vest.
Key Facts for Investor Verification
- Verify the impact of the revised 2016 AFCF targets on executive compensation costs and potential dilution.
- Monitor GSK's TSR ranking relative to the specified comparator group of 10 pharmaceutical companies.
- Confirm the actual R&D investment levels in the Pharmaceuticals and HIV sectors to validate the rationale for the target adjustment.
- Review future filings for the disclosure of the confidential R&D new product performance targets upon the conclusion of the 2017-2019 period.